January 24, 2014 (Shareholders Foundation) - An investigation on behalf of investors of United Therapeutics Corporation (NASDAQ:UTHR) shares over potential securities laws violations by United Therapeutics Corporation and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of United Therapeutics Corporation (NASDAQ:UTHR) concerning whether a series of statements by United Therapeutics Corporation regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On December 9, 2013: United Therapeutics Corporation (NASDAQ:UTHR) announced that it has received a subpoena from the Office of the Inspector General of the Department of Health and Human Services reflecting an investigation by the United States Department of Justice, principally represented by the United States Attorneys Office in Baltimore.

United Therapeutics Corporation said that the subpoena requests documents regarding Remodulin (treprostinil) Injection, Tyvaso (treprostinil) Inhalation Solution and Adcirca (tadalafil) Tablets, including the companys marketing practices relating to these products.

United Therapeutics Corporation reported that its annual Total Revenue rose from $358.88 million in 2009 to $916.08 million in 2012 and that its respective Net Income increased from $19.46 million to $304.44 million.

Shares of United Therapeutics Corporation (NASDAQ:UTHR) grew from $41.73 per share in November 2009 to as high as $114.51 per share in late December 2013.

On January 24, 2014, NASDAQ:UTHR shares closed at $107.54 per share.